Biopure(Cambridge, Massachusetts) reported receiving notification from Nasdaq that the company has regained compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq.

Biopure manufactures intravenously administered pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body’s tissues. The company is developing Hemopure, or HBOC-201, for a potential indication in cardiovascular ischemia and, in collaboration with the U.S. Naval Medical Research Center, for an out-of-hospital trauma indication. The product is approved in South Africa for treating surgery patients who are acutely anemic and for eliminating, delaying or reducing allogeneic red blood cell transfusions in these patients.

Healthcare Realty Trust dismisses KPMG

Healthcare Realty Trust (Nashville, Tennessee) has reported that the audit committee of the company’s board has dismissed KPMG as its independent registered public accounting firm. The company said it expects to engage a replacement accounting firm “as soon as possible.”

On June 23, the company will furnish its unaudited results of operations and financial condition for the year ended Dec. 31, 2004, and the three months ended March 31, 2005. On June 24, at 11 a.m., EDT, Healthcare Realty Trust will hold a conference call to discuss earnings results, general operations of the company and industry trends.

Healthcare Realty Trust is a real estate investment trust that integrates owning, managing and developing real estate properties associated with the delivery of healthcare services throughout the U.S.

As of December 31, 2004, the company had investments of about $1.9 billion in 253 real estate properties or mortgages, totaling about 13.2 million square feet.